HC Wainwright Reiterates Buy Rating for MCRB
Analyst Matthew Keller reaffirms a buy rating with a $12 price target, a 76.21% upside from the current price.
Key Points
- HC Wainwright's analyst Matthew Keller reiterated a buy rating for MCRB with a $12 price target on June 23, 2026.
- HC Wainwright's $12 price target implies 76.21% upside from Seres Therapeutics, Inc.'s ($MCRB) current $6.81 share price.
- On Tuesday, MCRB shares traded at $6.6, with recent insider activity including planned sales by executives.
- Other funds like Vanguard Capital opened new positions in MCRB, while Susquehanna reduced its holdings by 41.5%.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright's analyst Matthew Keller reiterated his buy rating on MCRB with a price target of $12 on June 23, 2026. This latest analyst action underscores continued confidence in the company’s prospects.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in MCRB
Several institutional investors have shown interest in MCRB. Flagship Pioneering maintained its position with 1,155,850 shares worth about $10.3 million. Vanguard Capital Management opened a new position with 294,143 shares valued at approximately $2.6 million. Marshall Wace increased its stake by 19,362 shares, bringing its total to 139,539 shares worth nearly $1.24 million, a 16.1% increase. Meanwhile, Vontobel Holding raised its holdings by 35,234 shares, ending with 138,468 shares valued at about $1.23 million, marking a 34.1% increase. On the other hand, Susquehanna International Group trimmed its stake by 74,590 shares, now holding 105,339 shares valued at $934,357, a 41.5% decrease.
Seres Therapeutics, Inc. Stock Up 33.3%
On Tuesday, shares of MCRB traded around $6.6. Despite the analyst's optimistic outlook, the company's stock performance remains a focus for investors considering its current market conditions.
$MCRB price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Seres Therapeutics, Inc.
Recent insider transactions at MCRB include several planned sales on May 18, 2026. Brady Kelly, the Chief Operating Officer, sold 59 shares at $7.53 each. Matthew Henn, Chief Scientific Officer, and Thomas Desrosier, Chief Legal Officer, also sold shares under planned transactions. Eric Shaff, however, bought 722 shares on May 15, 2026, without a pre-planned arrangement.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its buy rating for MCRB with a $12 price target. Canaccord Genuity previously maintained its buy rating with a $22 target on March 13, 2026. The consensus among analysts remains positive, with a buy recommendation and a mean target price yet to be determined.
Bottom Line
HC Wainwright's reaffirmation of its buy rating for MCRB with a $12 target reflects sustained optimism from analysts. The stock's recent trading price of $6.6 highlights potential growth opportunities in line with analyst expectations. Institutional activities and insider transactions provide additional context for investors monitoring MCRB's market movements.
Get Seres Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MCRB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.